|Application ||WB, IHC-P, E|
|Other Accession||NP_758965.1, NP_066274.1|
|Calculated MW||21061 Da|
|Antigen Region||122-149 aa|
|Other Names||Cancer/testis antigen 2, CT2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 62, CT62, L antigen family member 1, LAGE-1, CTAG2, ESO2, LAGE1|
|Target/Specificity||This CTAG2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 122-149 amino acids from the Central region of human CTAG2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CTAG2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Testis and very low level in placenta and in some uterus samples. Observed in 25-50% of tumor samples of melanomas, non-small-cell lung carcinomas, bladder, prostate and head and neck cancers|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes an autoimmunogenic tumor antigen that belongs to the ESO/LAGE family of cancer-testis antigens. This protein is expressed in a wide array of cancers including melanoma, breast cancer, bladder cancer and prostate cancer. This protein is also expressed in normal testis tissue. An alternative open reading frame product of this gene has been described in PMID 10399963. This alternate protein, termed CAMEL, is a tumor antigen that is recognized by melanoma-specific cytotoxic T-lymphocytes. Alternate splicing results in multiple transcript variants. [provided by RefSeq].
Wang, X.Y., et al. Oncol. Rep. 21(3):713-719(2009)
Shao, Y., et al. J. Cancer Res. Clin. Oncol. 134(4):495-502(2008)
Andrade, V.C., et al. Cancer Immun. 8, 2 (2008) :
Kan, T., et al. Oncology 70(1):25-33(2006)
Scanlan, M.J., et al. Immunol. Rev. 188, 22-32 (2002) :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.